JWH-018 binds to both the CB1 and CB2 receptors. The results of JWH-018 are primarily attributable into the binding and activation of CB1 receptors. In follow, the compound suppresses the release of neurotransmitters from the central nervous procedure, which clarifies the multitude of outcomes.